SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

BACKGROUND The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood. METHODS We obtained DNA samples from leukemia cells in 91 patients with chronic lymphocytic leukemia and performed massively parallel sequencing of 88 whole exomes and whole genomes, together with sequencing of matched germline DNA, to characterize the spectrum of somatic mutations in this disease. RESULTS Nine genes that are mutated at significant frequencies were identified, including four with established roles in chronic lymphocytic leukemia (TP53 in 15% of patients, ATM in 9%, MYD88 in 10%, and NOTCH1 in 4%) and five with unestablished roles (SF3B1, ZMYM3, MAPK1, FBXW7, and DDX3X). SF3B1, which functions at the catalytic core of the spliceosome, was the second most frequently mutated gene (with mutations occurring in 15% of patients). SF3B1 mutations occurred primarily in tumors with deletions in chromosome 11q, which are associated with a poor prognosis in patients with chronic lymphocytic leukemia. We further discovered that tumor samples with mutations in SF3B1 had alterations in pre-messenger RNA (mRNA) splicing. CONCLUSIONS Our study defines the landscape of somatic mutations in chronic lymphocytic leukemia and highlights pre-mRNA splicing as a critical cellular process contributing to chronic lymphocytic leukemia.

[1]  J.,et al.  The New England Journal of Medicine , 2012 .

[2]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[3]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[4]  Š. Pospíšilová,et al.  Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Potter,et al.  Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. , 2011, ACS chemical biology.

[6]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[7]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[8]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[9]  J. Valcárcel,et al.  Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. , 2011, Genes & development.

[10]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[11]  B. Spencer‐Dene,et al.  FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation , 2011, The Journal of experimental medicine.

[12]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[13]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[14]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[15]  A. Kibel The genomic complexity of primary human prostate cancer: Berger MF, Lawrence MS, Demichelis F, et al (The Broad Inst of Harvard and MIT, Cambridge, MA; Weill Cornell Med College, NY; et al) Nature 470:214-220, 2011 § , 2011 .

[16]  Albert Gutierrez,et al.  LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. , 2010, Blood.

[17]  H. Döhner,et al.  TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Döhner,et al.  From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.

[19]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[20]  R. Wollman,et al.  A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. , 2009, Molecular cell.

[21]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[22]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[23]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[24]  V. Boussiotis,et al.  Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. , 2008, Blood.

[25]  B. Rinkevich,et al.  The DDX3 subfamily of the DEAD box helicases: divergent roles as unveiled by studying different organisms and in vitro assays. , 2007, Current medicinal chemistry.

[26]  Rob Pieters,et al.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors , 2007, The Journal of experimental medicine.

[27]  T. Owa,et al.  Splicing factor SF3b as a target of the antitumor natural product pladienolide , 2007, Nature Chemical Biology.

[28]  M. Hagiwara,et al.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.

[29]  C. Chalfant,et al.  SAP155 Binds to ceramide‐responsive RNA cis‐element 1 and regulates the alternative 5′ splice site selection of Bcl‐x pre‐mRNA , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  T. Stankovic,et al.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.

[31]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Min Gyu Lee,et al.  An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation , 2005, Nature.

[33]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[34]  K. Nakayama,et al.  Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.

[35]  C. Fegan,et al.  The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. , 2003, Blood.

[36]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[37]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[38]  A. H. Dinsmore,et al.  New England , 1894, Letters from America.